GPCR NATIVE COMPLEX
Dead / Abandoned — Abandoned — failure to respond (as of 20 Dec 2023)
What this means for you
This application is over — abandoned 02 Nov 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97148593
- Mark type
- Stylized text
- Filed
- 30 Nov 2021
- Abandoned
- 02 Nov 2023
- Attorney of record
- Shane Rumbaugh
Goods and services
- Class 001 — Chemicals: Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for scientific research use; chemical reagents for use in genetic research
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for modulating G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical preparations for use in neurology, endocrinology, metabolism, immunology, oncology, cardiovascular medicine, gastroenterology, pain, anesthesiology, dermatology, ophthalmology, psychiatry, pulmonology, urology, reproductive medicine, and orthopedics; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; pharmaceutical preparations for targeting GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; biological preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for use in medical research
- Class 040 — Treatment of materials: Custom manufacture of biochemical systems, namely, custom manufacture of systems for targeting G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders
- Class 042 — Scientific and technological services: Bio-technology and scientific services, namely, research, and production and development services relating to bio-technology and science, namely, G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical research and development; Scientific and technological services, namely, biological and bio-technology analysis services; scientific and medical laboratory services; biochemistry research services, namely, treating therapeutic targets through chemical and biochemical preparations
- Class 044 — Medical, beauty and agricultural services: Providing a website featuring information about the treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders
Owner
- Septerna, Inc., San Francisco, CA, US
Prosecution history
- 21 Dec 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 20 Dec 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 20 Dec 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 20 Jul 2023 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 20 Jul 2023 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 01 May 2023 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 01 May 2023 — FINAL REFUSAL E-MAILED
- 01 May 2023 — FINAL REFUSAL WRITTEN
- 15 Mar 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Mar 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 Mar 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 13 Sept 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Sept 2022 — NON-FINAL ACTION E-MAILED
- 13 Sept 2022 — NON-FINAL ACTION WRITTEN
- 09 Sept 2022 — ASSIGNED TO EXAMINER